Soleno Therapeutics Faces Class Action Lawsuit Deadline

Investors have until May 5, 2026 to join lawsuit over alleged securities fraud

Mar. 18, 2026 at 3:18am

Got story updates? Submit your updates here. ›

Kahn Swick & Foti, LLC, a national securities litigation law firm, has notified investors in Soleno Therapeutics, Inc. of a class action lawsuit related to alleged securities fraud between March 26, 2025 and November 4, 2025. The lawsuit alleges that Soleno and its executives failed to disclose material information about potential safety concerns with the company's only commercial product, DCCR, for the treatment of Prader-Willi syndrome.

Why it matters

This case highlights the importance of transparency and full disclosure for publicly traded companies, especially regarding the safety and efficacy of their products. The alleged failure to disclose material information could have significant implications for Soleno's commercial viability and reputation.

The details

According to the complaint, Soleno is accused of systematically minimizing, mischaracterizing, and/or failing to disclose substantial evidence of potential safety concerns associated with the administration of DCCR, including indications of excessive fluid retention among clinical trial participants. This allegedly resulted in DCCR having materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch.

  • The class action lawsuit covers the period from March 26, 2025 to November 4, 2025.
  • Investors have until May 5, 2026 to apply to be a lead plaintiff in the case.

The players

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Kahn Swick & Foti, LLC

A national boutique securities litigation law firm that has been ranked among the top 10 firms nationally based on total settlement value.

Charles C. Foti, Jr.

The former Attorney General of Louisiana and a partner at Kahn Swick & Foti, LLC.

Got photos? Submit your photos here. ›

What they’re saying

“Soleno investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-slno/ to learn more.”

— Lewis Kahn, Managing Partner, Kahn Swick & Foti, LLC (Press Release)

What’s next

The judge in the case will decide on May 5, 2026 whether to appoint a lead plaintiff for the class action lawsuit.

The takeaway

This case highlights the importance of full transparency and disclosure for publicly traded companies, especially regarding the safety and efficacy of their products. Investors should be vigilant in monitoring the actions of companies they invest in and be prepared to take legal action if they believe material information has been withheld.